Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
US9701672B2 · kind B2 · utility
8Cited by
2References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 5, 2015 |
| Grant date | Jul 11, 2017 |
| Priority date | — |
| Expiry date | Mar 5, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.